Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | BCR | P11274 | 2/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.35 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16719820 | 0.86 | ABL1 (0.43) | TGFBR1MAPKAPK2ABL1BCRABCB1 | |
| SCHEMBL28895988 | 0.84 | TGFBR1 (0.45) | TGFBR1MAPKAPK2STIM1ORAI1FYN | |
| SCHEMBL16719529 | 0.82 | IDO1 (0.39) | STIM1ORAI1FYNL3MBTL1MAPK1 | |
| SCHEMBL16719832 | 0.76 | SMN1; SMN2 (0.44) | TGFBR1MAPKAPK2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL2746986 | 0.68 | CA12 (0.43) | L3MBTL1LMNATDP1ALDH1A1MAPT | |
| SCHEMBL16720648 | 0.67 | IDO1 (0.46) | TGFBR1FYNMAPK1ALDH1A1MAPT | |
| SCHEMBL29482126 | 0.65 | STIM1 (0.57) | ABL1BCRSTIM1ORAI1WNK1 | |
| SCHEMBL21311114 | 0.65 | STIM1 (0.57) | ABL1BCRSTIM1ORAI1WNK1 | |
| SCHEMBL692388 | 0.62 | CA12 (0.46) | L3MBTL1TDP1ALDH1A1KDM4EHPGD | |
| SCHEMBL20646292 | 0.61 | PARP1 (0.59) | ABL1BCRABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396551-A1 | EBNA1 Inhibitors and Their Method of Use | WISTAR INST (US) | 2022-12-15 | — | — | US | claimed |
| US-11242317-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2022-02-08 | — | — | US | claimed |
| EP-3068758-B1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2021-09-08 | — | — | EP | claimed |
| US-20200181078-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2020-06-11 | — | — | US | claimed |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | claimed |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-06 | — | — | US | claimed |
| EP-3068758-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | The Wistar Institute Of Anatomy And Biology (US) | 2016-09-21 | — | — | EP | claimed |
| WO-2015073864-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2015-05-21 | — | — | WO | claimed |
| US-12258314-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2025-03-25 | — | — | US | disclosed |
| US-20220396551-A1 | EBNA1 Inhibitors and Their Method of Use | WISTAR INST (US) | 2022-12-15 | — | — | US | disclosed |
| US-11242317-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3068758-B1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20200181078-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2020-06-11 | — | — | US | disclosed |
| US-10421718-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-9856214-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-06 | — | — | US | disclosed |
| EP-3068758-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | The Wistar Institute Of Anatomy And Biology (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015073864-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258314-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | TGFBR1 2814/4885MAPKAPK2 3553/4885ABL1 539/4885 |
| US-11242317-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | TGFBR1 2814/4885MAPKAPK2 3553/4885ABL1 539/4885 |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | MCM5, EBNA1BP2, MLLT1 | TGFBR1 2685/4885MAPKAPK2 3596/4885ABL1 584/4885 |
| US-20200181078-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | EBNA1BP2, MLLT1, PML | TGFBR1 2814/4885MAPKAPK2 3553/4885ABL1 539/4885 |
| US-10421718-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | TGFBR1 2814/4885MAPKAPK2 3553/4885ABL1 539/4885 |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | EBNA1BP2, MLLT1, PML | TGFBR1 2814/4885MAPKAPK2 3553/4885ABL1 539/4885 |
| US-20220396551-A1 | EBNA1 Inhibitors and Their Method of Use | EBNA1BP2, MLLT1, PML | TGFBR1 2814/4885MAPKAPK2 3553/4885ABL1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.